Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-19-054172
Filing Date
2019-10-15
Accepted
2019-10-15 16:30:25
Documents
6
Period of Report
2019-12-09
Effectiveness Date
2019-10-15

Document Format Files

Seq Description Document Type Size
1 DEF 14A tv530721-def14a.htm DEF 14A 179022
2 GRAPHIC lg_protalix.jpg GRAPHIC 5865
3 GRAPHIC pc_tv530721proxy01-lr.jpg GRAPHIC 241948
4 GRAPHIC pc_tv530721proxy02-lr.jpg GRAPHIC 320119
5 GRAPHIC sg_drorbashan.jpg GRAPHIC 4652
6 GRAPHIC sg_eyalrubin-bw.jpg GRAPHIC 168468
  Complete submission text file 0001104659-19-054172.txt   1168747
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 191151250
SIC: 2836 Biological Products, (No Diagnostic Substances)